Evidence map›Paper›PMID 35486218›Full record

ReviewCurrent rheumatology reports2022

Cannabis for Rheumatic Disease Pain: a Review of Current Literature.

William Benjamin Nowell, Kelly Gavigan, Stuart L Silverman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. The Elusive Truth of Cannabinoids for Rheumatic Pain.Current rheumatology reports · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

William Benjamin NowellGlobal Healthy Living Foundation, 515 N. Midland Ave, Upper Nyack, NY, 10960, USA. bnowell@ghlf.org.ORCID http://orcid.org/0000-0002-4951-6476
Kelly GaviganGlobal Healthy Living Foundation, 515 N. Midland Ave, Upper Nyack, NY, 10960, USA.ORCID http://orcid.org/0000-0003-2615-4940
Stuart L SilvermanCedars-Sinai Medical Center, Beverly Hills, CA, USA.
Global Healthy Living Foundation · USCedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewChanging attitudes about marijuana have led to an increase in use of medicinal marijuana, especially for painful chronic conditions. Patients ask rheumatologists for guidance on this topic. This review provides up-to-date information on the safety and efficacy of medicinal cannabis for rheumatic disease pain. RECENT

findingsThe number of publications related to rheumatic disease and cannabis has increased, but recent literature skews heavily toward reviews vs primary research. Data supporting a role for cannabinoids in rheumatic disease continue to grow. Observational and survey studies show increased use of medicinal cannabis, both by people with rheumatic disease and the general population, and suggest that patients find these treatments beneficial. Prospective studies, however, including randomized controlled clinical trials, are rare and sorely needed. As medicinal cannabis use for rheumatic diseases rises, despite lack of evidence, we review the sparse data available and provide tips for conversations about medicinal cannabis for rheumatologists.

Indexed as

CannabisChronic PainMedical MarijuanaMusculoskeletal PainRheumatic DiseasesAnalgesicsHumansProspective StudiesAnalgesicsMedical MarijuanaCannabisChronic painEndocannabinoidFibromyalgiaMarijuanaOsteoarthritisRheumatoid arthritisSystemic lupus erythematosus

Identifiers

PMID35486218
OpenAlexW4225113773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.